for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aduro's pancreatic cancer drug fails in mid-stage study

(Reuters) - Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study.

In the study, patients were given either CRS-207 or chemotherapy or a combination of CRS-207 with Aduro’s GVAX Pancreas, the company said on Monday.

Aduro’s shares fell 33 percent to $7.14 in premarket trading.

Reporting by Ankur Banerjee in Bengaluru; Editing by Kirti Pandey

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up